Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Change in Accured Expenses (2017 - 2023)

Historic Change in Accured Expenses for Dianthus Therapeutics (DNTH) over the last 6 years, with Q2 2023 value amounting to -$1.7 million.

  • Dianthus Therapeutics' Change in Accured Expenses fell 16982.34% to -$1.7 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$2.6 million, marking a year-over-year decrease of 70914.83%. This contributed to the annual value of $973000.0 for FY2022, which is 53594.77% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Change in Accured Expenses of -$1.7 million as of Q2 2023, which was down 16982.34% from -$3.3 million recorded in Q1 2023.
  • In the past 5 years, Dianthus Therapeutics' Change in Accured Expenses ranged from a high of $3.7 million in Q4 2019 and a low of -$3.3 million during Q1 2023
  • For the 4-year period, Dianthus Therapeutics' Change in Accured Expenses averaged around -$136818.2, with its median value being -$623000.0 (2022).
  • As far as peak fluctuations go, Dianthus Therapeutics' Change in Accured Expenses surged by 64388.78% in 2019, and later tumbled by 28870.78% in 2023.
  • Over the past 4 years, Dianthus Therapeutics' Change in Accured Expenses (Quarter) stood at $3.7 million in 2019, then crashed by 168.62% to -$2.5 million in 2020, then soared by 159.64% to $1.5 million in 2022, then plummeted by 210.66% to -$1.7 million in 2023.
  • Its last three reported values are -$1.7 million in Q2 2023, -$3.3 million for Q1 2023, and $1.5 million during Q4 2022.